Research ExplorerPublicationsAllogeneic stem cell transplantation in patients with atypic...

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Standard

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. / Onida, Francesco; de Wreede, Liesbeth C; van Biezen, Anja; Eikema, Diderik-Jan; Byrne, Jenny L; Iori, Anna P; Schots, Rik; Jungova, Alexandra; Schetelig, Johannes; Finke, Jürgen; Veelken, Hendrik; Johansson, Jan-Erik; Craddock, Charles; Stelljes, Matthias; Theobald, Matthias; Holler, Ernst; Schanz, Urs; Schaap, Nicolaas; Bittenbring, Jörg; Olavarria, Eduardo; Chalandon, Yves; Kröger, Nicolaus.

In: BRIT J HAEMATOL, Vol. 177, No. 5, 06.2017, p. 759-765.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Onida, F, de Wreede, LC, van Biezen, A, Eikema, D-J, Byrne, JL, Iori, AP, Schots, R, Jungova, A, Schetelig, J, Finke, J, Veelken, H, Johansson, J-E, Craddock, C, Stelljes, M, Theobald, M, Holler, E, Schanz, U, Schaap, N, Bittenbring, J, Olavarria, E, Chalandon, Y & Kröger, N 2017, 'Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation', BRIT J HAEMATOL, vol. 177, no. 5, pp. 759-765. https://doi.org/10.1111/bjh.14619

APA

Onida, F., de Wreede, L. C., van Biezen, A., Eikema, D-J., Byrne, J. L., Iori, A. P., Schots, R., Jungova, A., Schetelig, J., Finke, J., Veelken, H., Johansson, J-E., Craddock, C., Stelljes, M., Theobald, M., Holler, E., Schanz, U., Schaap, N., Bittenbring, J., ... Kröger, N. (2017). Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. BRIT J HAEMATOL, 177(5), 759-765. https://doi.org/10.1111/bjh.14619

Vancouver

Onida F, de Wreede LC, van Biezen A, Eikema D-J, Byrne JL, Iori AP et al. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. BRIT J HAEMATOL. 2017 Jun;177(5):759-765. https://doi.org/10.1111/bjh.14619

Bibtex

@article{8909a5c082984cda90de1a6fd2d00b8d,
title = "Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation",
abstract = "Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.",
keywords = "Adult, Aged, Disease-Free Survival, Female, Graft Survival, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Male, Middle Aged, Recurrence, Retrospective Studies, Risk Factors, Transplantation, Homologous, Journal Article",
author = "Francesco Onida and {de Wreede}, {Liesbeth C} and {van Biezen}, Anja and Diderik-Jan Eikema and Byrne, {Jenny L} and Iori, {Anna P} and Rik Schots and Alexandra Jungova and Johannes Schetelig and J{\"u}rgen Finke and Hendrik Veelken and Jan-Erik Johansson and Charles Craddock and Matthias Stelljes and Matthias Theobald and Ernst Holler and Urs Schanz and Nicolaas Schaap and J{\"o}rg Bittenbring and Eduardo Olavarria and Yves Chalandon and Nicolaus Kr{\"o}ger",
note = "{\textcopyright} 2017 John Wiley & Sons Ltd.",
year = "2017",
month = jun,
doi = "10.1111/bjh.14619",
language = "English",
volume = "177",
pages = "759--765",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

AU - Onida, Francesco

AU - de Wreede, Liesbeth C

AU - van Biezen, Anja

AU - Eikema, Diderik-Jan

AU - Byrne, Jenny L

AU - Iori, Anna P

AU - Schots, Rik

AU - Jungova, Alexandra

AU - Schetelig, Johannes

AU - Finke, Jürgen

AU - Veelken, Hendrik

AU - Johansson, Jan-Erik

AU - Craddock, Charles

AU - Stelljes, Matthias

AU - Theobald, Matthias

AU - Holler, Ernst

AU - Schanz, Urs

AU - Schaap, Nicolaas

AU - Bittenbring, Jörg

AU - Olavarria, Eduardo

AU - Chalandon, Yves

AU - Kröger, Nicolaus

N1 - © 2017 John Wiley & Sons Ltd.

PY - 2017/6

Y1 - 2017/6

N2 - Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

AB - Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

KW - Adult

KW - Aged

KW - Disease-Free Survival

KW - Female

KW - Graft Survival

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

KW - Male

KW - Middle Aged

KW - Recurrence

KW - Retrospective Studies

KW - Risk Factors

KW - Transplantation, Homologous

KW - Journal Article

U2 - 10.1111/bjh.14619

DO - 10.1111/bjh.14619

M3 - SCORING: Journal article

C2 - 28369779

VL - 177

SP - 759

EP - 765

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 5

ER -